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Background: Hip fractures are a common type of fragility fracture that afflict 293,000 Americans (over 5,000 per
week) and 35,000 Canadians (over 670 per week) annually. Despite the large population impact the optimal fixation
technique for low energy femoral neck fractures remains controversial. The primary objective of the FAITH study is
to assess the impact of cancellous screw fixation versus sliding hip screws on rates of revision surgery at 24 months
in individuals with femoral neck fractures. The secondary objective is to determine the impact on health-related
quality of life, functional outcomes, health state utilities, fracture healing, mortality and fracture-related
adverse events.
Methods/Design: FAITH is a multi-centre, multi-national randomized controlled trial utilizing minimization to
determine patient allocation. Surgeons in North America, Europe, Australia, and Asia will recruit a total of at least
1,000 patients with low-energy femoral neck fractures. Using central randomization, patients will be allocated to
receive surgical treatment with cancellous screws or a sliding hip screw. Patient outcomes will be assessed at one
week (baseline), 10 weeks, 6, 12, 18, and 24 months post initial fixation. We will independently adjudicate revision
surgery and complications within 24 months of the initial fixation. Outcome analysis will be performed using a Cox
proportional hazards model and likelihood ratio test.
Discussion: This study represents major international efforts to definitively resolve the treatment of low-energy
femoral neck fractures. This trial will not only change current Orthopaedic practice, but will also set a benchmark
for the conduct of future Orthopaedic trials.
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Hip fractures are a common type of fragility fracture
that afflict 293,000 Americans (over 5,000 per week) and
35,000 Canadians (over 670 per week) annually [1,2].
The prevalence of hip fractures is likely to exceed
500,000 annually in the United States and 88,000 in
Canada over the next 40 years [3,4]. The estimated an-
nual health care costs will reach a staggering $17 billion
in the United States [5] and $650 million in Canada
[6,7]. Hip fractures are associated with a 30% mortality
rate at 1 year [8] and profound temporary and some-
times permanent impairment of independence and qual-
ity of life [9,10]. The disability-adjusted life-years lost as
a result of hip fractures ranks in the top 10 of all cause
disability globally [3].
Intracapsular fractures (also known as femoral neck
fractures) may be either undisplaced or displaced. In-
ternal fixation, in which a mechanical implant fixes the
two segments of bone together, is the best way to man-
age undisplaced fractures [11] and, depending on patient
characteristics and surgeon preference, can be used to
manage displaced fractures as well [12].
Complications of internal fixation include avascular
necrosis of the femoral head as well as early implant
failure and nonunion [13,14]. Approximately 30% of
surgically treated hip fractures require revision surgery
[15-17]. These revisions are associated with a large bur-
den of morbidity and appreciable mortality. Even pa-
tients who do not require revision surgery may have
long term functional limitation due to soft tissue dam-
age at the time of surgery.
The most popular approaches to internal fixation in-
clude multiple cancellous screws or a single compression
screw and side plate (i.e., sliding hip screws). Both ap-
proaches have strong physiologic rationale and ardent
advocates; however, there is no consensus regarding the
optimal approach for management of intracapsular hip
fractures [12].
Multiple cancellous screws
Advocates of multiple cancellous screws focus upon its
superior torsional stability, limited disruption of femoral
head blood supply, and minimally invasive insertion
[18-22]. Based on physiologic and observational studies,
most surgeons use 3 parallel cancellous screws in a tri-
angular (typically inverted) orientation [12,20]. Proponents
of cancellous screws further argue that small diameter
screws retain more viable bone after insertion compared
to the larger sliding hip screws [18-22]. Retaining more
cancellous bone optimizes vascularity and thus may re-
duce the risk of avascular necrosis of the femoral head. A
randomized controlled trial (RCT) comparing 3 cancel-
lous screws with a larger sliding hip screw found 3.5-fold
greater femoral head vascularity at follow-up bone scanningwith screws [22]. Surgeons can insert cancellous screws
using 3 small stab incisions with limited blood loss and
operating time. This minimally invasive approach may
limit damage to the soft tissues around the hip and plaus-
ibly lead to better patient function and general wellbeing.
Sliding hip screws
Despite the popularity of cancellous screw fixation, there
is a strong biologic rationale supporting the use of slid-
ing hip screws, a more biomechanically stable construct,
in older patients with osteopenia or osteoporosis [23].
Cancellous screw fixation improves torsional strength;
however, implant failures typically occur with bending
and vertical shear loads (i.e., with weight-bearing). The
sliding hip screw, the gold standard approach in treating
inter-trochanteric fractures of the hip, has gained popu-
larity as an alternative in the management of femoral
neck fractures. Proponents of the sliding hip screw be-
lieve its superior biomechanical properties and greater
fracture stability in osteoporotic bone should decrease
the need for revision surgery. Sliding hip screw con-
structs have shown 2-fold greater maximal strength and
less displacement under physiologic loading conditions
compared to cannulated screws. In a cadaveric model,
the sliding hip screw performed better than cancellous
screws in stabilizing unstable femoral neck fractures
under cyclic loading [21]. The sliding hip screw performed
better in osteoporotic bone and was less sensitive to de-
cline in bone mineral density than screws [21]. Newer
minimally invasive techniques allow sliding hip screws to
be inserted with small incisions and smaller side plates
with limited blood loss and operating times [24].
Inconclusive clinical evidence
Bhandari and colleagues conducted a systematic review
and meta-analysis comparing arthroplasty to internal fix-
ation in patients with displaced femoral neck fractures.
Results demonstrate that while it may increase surgical
mortality, arthroplasty reduced the need for revision sur-
gery (RR = 0.23, 95%; CI: 0.13-0.42, homogeneity p < 0.01)
[16]. The authors conducted a sensitivity analysis to ex-
plore reasons for variability and found that arthroplasty,
compared to internal fixation, appeared to decrease the
risk of revision far more when the method of internal fix-
ation was screws alone (RR = 0.11) than when the method
of internal fixation was a compression screw and side
plate (RR = 0.59) (p < 0.01 for difference in estimates).
A meta-analysis by Parker and colleagues evaluated 28
trials (N = 5547 patients) and reported no advantage of
any internal fixation technique over any other technique
[25]. The trials were small (range in sample sizes: 33 to
410), and methodologically limited. Only 5 RCTs evalu-
ated sliding hip screws versus cancellous screws (4 dis-
placed femoral neck fractures, 1 undisplaced femoral neck
The FAITH Investigators BMC Musculoskeletal Disorders 2014, 15:219 Page 3 of 15
http://www.biomedcentral.com/1471-2474/15/219fractures). These trials ranged in size from 33 to 209 pa-
tients and had few total outcome events (range: 3–34
events). When the data from these 5 studies were pooled,
the point estimate trended toward favouring sliding hip
screws compared to cancellous screws; however, the dif-
ference was not statistically significant.
In summary, both direct comparisons between sliding
hip screws and cancellous screws and indirect compari-
sons (comparing sliding hip screws and cancellous screws
separately to arthroplasty) suggest a possible benefit for a
sliding hip screw over multiple cancellous screws in redu-
cing the need for revision surgery. The indirect nature of
the comparison from the meta-analysis of arthroplasty
versus internal fixation, and the small sample sizes, meth-
odological limitations, and non-significant pooled esti-
mates from the direct comparisons, leaves the issue very
much in doubt.
Surgical management of hip fractures
Bhandari and colleagues contacted 442 surgeons in an
international survey [12] to explore surgeons’ opinions
regarding internal fixation for femoral neck fractures.
For undisplaced femoral neck fractures, 92% of surgeons
preferred internal fixation. Despite the evidence suggest-
ing the superiority of sliding hip screws, 90% of surgeons
preferred cancellous screws. In displaced hip fractures,
25% of surgeons preferred internal fixation when com-
pared with arthroplasty; and of those who preferred in-
ternal fixation, 68% preferred cancellous screws.
Methods/Design
Pilot and vanguard phase
We have successfully completed a pilot RCT (n = 80 pa-
tients) to assess the feasibility of the definitive FAITH trial.
The primary outcomes of the pilot study were the rates of
reoperation at 24 months to promote fracture healing, re-
lieve pain, treat infection, treat a peri-prosthetic fracture,
or improve function. We also collected functional out-
comes on all patients. Our pilot RCT demonstrated: (1)
our ability to recruit patients for the definitive trial; (2) in-
vestigator compliance with key aspects of the protocol; (3)
maintenance of data quality; (4) maintenance of high
follow-up rates; (5) our ability to organize trial procedures
in a multinational trial; and (6) overall event rates for our
primary outcome that support our sample size calculation.
We have also used the vanguard phase to optimize case
report forms and a manual of operations. To avoid a break
in funding and to maintain our momentum across recruit-
ing sites, the Vanguard phase transitioned into the defini-
tive trial phase without stopping. The rationale for the
definitive FAITH trial is supported by: (1) the substantial
burden of hip fracture injuries to both patients and the
healthcare system; (2) differences in the surgical manage-
ment of hip fractures; (3) a lack of clinical evidence toinform the optimal method of internal fixation; (4) the
demonstrated success of the pilot RCT.
Study objectives
The primary objective of the FAITH study is to evaluate
the effects of sliding hip screws versus cancellous screws
on revision surgery at 24 months post-injury. The sec-
ondary objectives are to determine the impact of sliding
hip screws versus cancellous screws on health-related
quality of life, functional outcomes, health state utilities,
fracture healing, mortality, and other adverse events
such as avascular necrosis, nonunion, malunion, implant
breakage or failure, and infection.
Study design
FAITH is a multi-centre, concealed RCT using minimization
to determine patient allocation. We will randomly assign a
minimum of 1,000 patients who have sustained a femoral
neck fracture to one of two treatment groups. The first
treatment group involves fixation of the fracture with mul-
tiple small diameter cancellous screws (i.e., cancellous
screw group). The second treatment group involves fixation
of the fracture with a single larger diameter screw with a
side plate (i.e., sliding hip screw group). We hypothesize
that sliding hip screws will have lower rates of re-operation
(primary outcome) and higher functional outcome scores
(secondary outcome) at 24 months when compared with
cancellous screws. The FAITH trial is registered at Clinical-
Trials.gov (Identifier NCT00761813) and has received
McMaster University Research Ethics Board approval
(REB#: 06–402) and approval from local ethics boards.
Randomization
We will randomize patients using minimization to ensure
balance on baseline covariates An automated Internet-
based randomization system centralized at the FAITH
Methods Centre at McMaster University, which we have
used successfully for other multicenter trials, will ensure
concealed randomization of eligible consenting patients.
Concealed randomization will be ensured through two
strategies: 1) the randomization sequence will be prede-
termined by research personal who are external to the
clinical sites who are determining patient eligibility; and
2) the internet-based randomization system will require
surgeons to enter patients into the trial before treatment
allocation is divulged. Minimization will be used to en-
sure balance between intervention groups for several
patient factors. The minimization approach takes into
account each pre-identified prognostic variable and
sums over the variables to allocate each patient to the
treatment that minimizes the current differences between
groups for those prognostic variables. Unlike stratified
randomization, minimization works toward minimizing
the total imbalance for all factors together instead of
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Based upon our international survey of surgeons [12]
and current evidence [27], we will minimize for the
following prognostic factors: (1) Age (i.e., 50–80 years
or >80 years (81 years or older)); (2) Undisplaced or
displaced femoral neck fractures; (3) Pre-fracture living
setting (i.e., institutionalized or not institutionalized);
(4) Pre-fracture functional status (i.e., using ambulatory
aid or independent ambulator); (5) American Society for
Anesthesiologists (ASA) Class (i.e., Class I/II or III/IV/V)
[28]; and (6) Centre.
Eligibility criteria
Eligible patients will meet all the following inclusion cri-
teria: (1) Men or women aged 50 years and older (with no
upper age limit); (2) Fracture of the femoral neck con-
firmed with anteroposterior and lateral hip radiographs,
computed tomography, or magnetic resonance imaging
(MRI); (3) Operative treatment of displaced fractures within
4 days of presenting to the emergency room, or operative
treatment of undisplaced fractures within 7 days of present-
ing to the emergency room; (4) Patient was ambulatory
prior to fracture, though they may have used an aid such
as a cane or a walker; (5) Anticipated medical optimization
for operative fixation of the hip; (6) Provision of informed
consent by patient or a legally appointed representative;
(7) No other major trauma (defined as an Injury Severity
Score >16); and (8) Low energy fracture, in the judgment
of the attending surgeon.
We will exclude patients meeting any of the following
criteria: (1) Patients not suitable for internal fixation
(i.e., severe osteoarthritis, rheumatoid arthritis, or patho-
logic fracture); (2) Associated major injuries of the lower
extremity (i.e., ipsilateral or contralateral fractures of the
foot, ankle, tibia, fibula, knee, or femur; dislocations of the
ankle, knee, or hip; or femoral head defects or fracture);
(3) Retained hardware around the affected hip; (4) Infec-
tion around the hip (i.e., soft tissue or bone); (5) Patients
with disorders of known bone metabolism except osteo-
porosis (i.e., Paget’s disease, renal osteodystrophy, osteo-
malacia); (6) Patients with a history of frank dementia that
would interfere with assessment of the primary outcome
(i.e., revision surgery at 24 months); (7) Likely problems,
in the judgment of the investigators, with maintaining
follow-up (i.e., patients with no fixed address, report a
plan to move out of town, or intellectually challenged pa-
tients without adequate family support); and (8) Exclusion
of a patient because of enrolment in another ongoing drug
or surgical intervention trial will be left to the discretion
of the attending surgeon, on a case-by-case basis.
Patient recruitment and screening
Data will be collected from academic hospitals in Australia,
Canada, England, Germany, India, Norway, The Netherlands,and The United States. A complete list of clinical sites can
be obtained from the corresponding author upon request.
All patients presenting to participating surgeons with a di-
agnosed femoral neck fracture will be screened. Figure 1
shows the patient identification and screening procedures.
Informed consent will be obtained from all eligible patients
by qualified clinical site personnel who are knowledgeable
about the study. If a patient lacks capacity and is deemed
unable to consent, informed consent may be obtained
from the patient’s legally authorized representative.
We will enroll all patients who meet the eligibility cri-
teria and document reasons for failure to randomize all
eligible patients. We will also document all patients
screened for eligibility and record them as: (1) Eligible
and included; (2) Eligible and missed; or (3) Excluded.
The Central Adjudication Committee (CAC) will adjudi-
cate all situations where eligibility is in doubt.Study interventions
Cancellous screw
Patients allocated to the cancellous screw group will re-
ceive multiple threaded screws (with a minimum of 2
screws and a minimum diameter of 6.5 mm). Surgeons
will be allowed to use any threaded screw or hook pin (i.
e., Gouffon, Uppsala, von Bahr, Hansson hook pins, etc.)
or cancellous threaded screw (i.e., cannulated or non-
cannulated, Ace, AO/Anklylosing Spondylitis Inter-
national Federation (ASIF), Asnis, Richards, etc.). Sur-
geons will follow the technique guides associated with
the screw manufacturers. No injectable bone substitutes
will be allowed for augmentation of the implant fixation.
Surgeons will document the following: (1) Number of
screws; (2) Number of washers; (3) Manufacturer; (4)
Reduction technique; (5) Decision to perform a capsulot-
omy or aspirate intracapsular hematoma; and (6) Screw
configurations, especially of the third screw (outside of 2
critical placements inferiorly and posteriorly).Sliding hip screw
Patients allocated to the sliding hip screws group will re-
ceive a single larger diameter partially threaded screw
affixed to the proximal femur with a side plate (with a
minimum of 2 holes and a maximum of 4 holes) and no
supplemental fixations. Surgeons will be permitted to
use any commercially available sliding hip screw implant
(i.e., Stryker, DePuy, Synthes, Smith and Nephew, Zimmer,
etc.), and will insert implants as per the manufacturers’
technical guides. The derotational kirschner wire should
penetrate the acetabulum to provide maximal resistance
to torsion. A centre-to-centre approach is recommended,
while avoiding a superior and anterior approach. Spiral
blades and helical screws are permitted, because they
function similarly to the sliding hip screw. It will be
Figure 1 Recruitment schedule (Baseline radiographs & Data collection).
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derotational screws are employed by the surgeon.
The use of a compression screw, manufacturer, reduction
technique, decision to perform a capsulotomy, aspiration
of intracapsular hematoma, and final screw position mea-
sured by the Tip Apex Distance will be documented and
based upon surgeon preference. No injectable bone substi-
tutes will be allowed for augmentation of the implant
fixation.Standardization of procedures and peri-operative care
We will recommend that clinical sites standardize key as-
pects of peri-operative care including: (1) Pre-operative
antibiotics (i.e., cephalosporins, or equivalent coverage)
administered before surgery and continued for 24 hours
post-operatively; (2) Pre-operative thromboprophylaxis
(i.e., Thromboembolic Disease (TED) Stockings, pneumatic
compression boots, or medical prophylaxis discontinued
in sufficient time to allow surgery as guided by Inter-
national Normalized Ratio (INR)/Partial Thromboplastin
Time (PTT)); (3) Post-operative thromboprophylaxis with
unfractionated Heparin, Low Molecular Weight Heparin
(LMWH), Warfarin, anti-platelet agents, or intermittent
pneumatic compression boots.Post-surgery, we will recommend that patients will be
weight-bearing as tolerated and then advanced according
to the attending surgeon’s best judgment (i.e., we will
permit touch weight-bearing for displaced fractures and
then advanced weight-bearing according to the surgeon’s
best judgment).
We will recommend that all patients in the study receive
600 mg of Calcium by mouth (PO) daily and/or vitamin D
1000 International Units (IU) per day (provided there are
no contraindications), or further investigation and treat-
ment of osteoporosis as recommended by a local osteopor-
osis expert/consultant as necessary. Appropriate nutritional
assessment with administration of oral micronutrient feeds
will also be provided as needed.
Patient positioning, fracture reduction, and surgical
exposure in the operating room will not be standardized
as these are highly variable across the world. However,
to ensure similar peri-operative care regimens it will be
recommended that participating centres standardize
these aspects of patient care. Finally, due to a lack of
evidence favouring a particular approach, the following
will be recorded but not standardized: (1) Use of pre-
operative traction; (2) Surgical delay; (3) Type of anesthetic
(i.e., general versus regional); and (4) Physiotherapy and
rehabilitation programs. All patients in the study will
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to surgery.
Study outcomes
Primary study endpoints
The primary study endpoint is re-operation within
24 months post initial surgery to promote fracture healing,
relieve pain, treat infection, or improve function including
the following: (1) Implant removal prior to fracture heal-
ing; (2) Revision surgery with another internal fixation im-
plant; (3) Revision surgery to arthroplasty; and (4) Soft
tissue procedures, especially incision and drainage for
deep infection at the bone implant interface. Classification
of the reason for revision surgery is as follows: (1) Implant
failure (2) Superficial or deep infection ; (3) Avascular ne-
crosis; (4) Hip instability; (5) Hip dislocation; (6) Open
wound; (7) Painful hardware; (8) Intractable pain due to
wear of the acetabulum; (9) Peri-prosthetic femur fracture;
and (10) Nonunion. Other classifications will be used if
applicable. Planned revision surgeries will not be consid-
ered study events (i.e., technical malreduction requiring
early revision). Criteria for the diagnosis of nonunion will
include a failure of the fracture to progress towards heal-
ing for at least 2 months on consecutive radiographs. This
will be evident as a persistent fracture line on radiograph,
continued pain with hip range of motion, and the inability
to weight-bear without pain. Avascular necrosis will be de-
fined as a process that is characterized pathologically by
bone marrow ischemia and eventual death of trabecular
bone. Infection will be classified according to the Center
for Disease Control Criteria [29].
Our choice of a 24 month follow-up period is dictated
by the following 2 factors: (1) We have established a
consensus among participating surgeons that the deci-
sion to re-operate on the hip fracture would occur
within the first 24 months following surgery in all, or
virtually all, patients and (2) Previous studies have re-
ported 100% of revision surgeries occurring between 2
and 12 months for undisplaced fractures and 70-100% in
24 months for displaced fractures. Although nonunion
and avascular necrosis may be present after 24 months,
previous studies suggest that 70-98% of revisions due to
nonunion and avascular necrosis occur within 24 months
[30,31]. Thus, we can expect that nearly all the revision
surgeries will occur within 24 months.
Secondary study endpoints
The secondary study endpoints include: (1) Health-related
quality of life; (2) Functional outcomes; (3) Health state
utilities; (4) Fracture healing; (5) Mortality; and (6) Other
adverse events such as avascular necrosis, non-union,
malunion, implant breakage or failure, and infection.
Health-related quality of life will be measured by the Short
Form-12 (SF-12) [32], the EuroQol-5 Dimensions (EQ-5D)[33], and the Western Ontario and McMaster Universities
Arthritis Index (WOMAC) [34].
The SF-12 is a 12-item questionnaire that measures
health-related quality of life across 8 domains. Both
physical and mental summary scores can be obtained.
Each domain is scored separately from 0 (lowest level)
to 100 (highest level). The instrument has been exten-
sively validated and has demonstrated good construct
validity, high internal consistency, and high test-retest
reliability [35] and is frequently used in orthopedics for
evaluating fracture outcomes.
The WOMAC index is self-administered and assesses
the three dimensions of pain, disability and joint stiffness
in knee and hip osteoarthritis using a battery of 24 ques-
tions [34]. It is a valid, reliable and responsive measure
of outcome, and has been used in several studies involving
a wide range of lower extremity conditions [36].
The EQ-5D is a comprehensive, compact health status
classification and health state preference system [33]. This
questionnaire is widely used and has demonstrated validity
and sensitivity in many populations [33,35].
Adjudication of study events
The CAC is comprised of a Chairperson plus three ortho-
paedic surgeon committee members. The CAC is respon-
sible for assessing patient eligibility (if in doubt) and they
will independently adjudicate radiographic characteristics
and quality of the surgery, fracture healing, revision sur-
geries, fracture-related complications (i.e., avascular ne-
crosis, nonunion, malunion, implant breakage or failure,
infection), and mortality. The adjudicators may review the
patients’ case report forms and x-rays and determine if the
reported outcome meets the criteria for being a study
event. Any disagreements between the adjudicators will be
discussed and resolved during consensus conference calls
with the CAC. If consensus cannot be reached after exten-
sive discussion, a vote will be permitted at the discretion
of the Chair. All decisions made by the committee will be
final. The CAC members will not be blinded to treatment
as it is not possible to accurately judge blinded images;
however, they will be blinded to the name and location of
the clinical site.
Study follow-up
Table 1 shows the schedule of study follow-up events. At
each follow-up, study outcomes will be recorded. Any
revision surgeries and adverse events will be recorded at
each visit. Missed follow-up visits or early withdrawal
will also be documented.
We will only withdraw patients for the following sce-
narios: (1) Patients withdraw consent for participation;
or (2) Patients are deemed lost to follow-up after the
24 month visit is overdue and all exhaustive measures
have been taken to locate the patient (see Figure 2 for a
Table 1 Schedule of events
Radiographs & event
forms
Pre-surgery Surgery Post-surgery
Screening Enrolment Baseline (Day 0) ≤ 48 hrs Post
surgery
D/C 1 wk
(24 hrs-10 ds)
10 wk
(8-12 wks)
6 mo
(5-7 mos)
9 mo
(8-10 mos)
12 mo
(11-13 mos)
18 mo
(17-19 mos)
24 mo
(≥24 mos)
Radiographs ● ● ● ● ●
Screening ●
Informed consent ●
Randomization ●
Baseline ●
Patient contact ● ● ● ● ● ● ● ● ● ●
Pre-Op care ●
Fracture characteristics ●
Surgical report ●
Post-Op care ●
Clinic or telephone
follow-up
● ● ● ● ● ● ●
RS * * * * * * * *
AE * * * * * * * * *
Hospital D/C ● * *
Missed
Follow-up * * * * * * *
Early W/D * * * * * * * *
*Complete forms when and/or if applicable.
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Figure 2 Limiting loss to follow-up; Reference: Sprague S, Leece P, Bhandari M, Tornetta P, Schemitsch E, Swiontkowski M, SPRINT
Investigators. Limiting loss to follow up in a multicentre randomized controlled trial in orthopaedic surgery. Controlled Clinical
Trials. 2003;24:719–725.
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follow-up). We will document the reasons for patient
withdrawal from the trial. For those patients who with-
draw from other study activities, we will seek their ap-
proval to collect clinical data from their medical and
hospital charts, and/or to contact them by telephone to
ask about the primary and secondary outcomes. We will
not withdraw patients even if the study protocol was not
adhered to (e.g., patient received wrong treatment arm,
occurrence of protocol deviations, missed follow-up
visits, etc.).
Protecting against sources of bias
Blinding
In the FAITH trial surgeons cannot be blinded since the
implants for the two treatment arms are easily distin-
guishable. Patients cannot be blinded because resulting
surgical scarring patterns from both fixation procedures
indicate which treatment was performed. Additionally,
some patients and/or their caregivers often wish to re-
view x-rays during clinic follow-up visits. Outcome as-
sessors cannot be blinded as blinded images create
difficulty in accurately adjudicating patient eligibility,
radiographic characteristics, surgical quality, healing,
and study events. Data analysts will be blinded.
Surgeon expertise
Similarly to other trials that evaluate two or more surgi-
cal interventions, there is a risk of differential expertise
bias [37]. However, training in both methods of internal
fixation examined in FAITH are standard training for
Orthopaedic surgeons. We will also recommend that
surgeons participating in the FAITH trial should meet 2criteria for expertise for either cancellous screw fixation
or sliding hip screw fixation: (1) Surgeons should have
performed at least 25 procedures (of either sliding hip
screws and/or cancellous screws) in their career (includ-
ing residency experience in which they assumed respon-
sibility for the procedure); and (2) Surgeons should
continue to perform the procedure (at least 5 per year of
either sliding hip screws and/or cancellous screws) in
the year prior to the trial start date. Additionally, we will
standardize aspects of the peri-operative care in order to
limit any potential expertise bias and differential use of
interventions. With these two procedures in place it is
unlikely that a significant degree of expertise bias will be
introduced into the trial.
Maximizing patient retention
Previous trials in hip fracture surgery have lost up to
50% of patients to follow-up [16]. To avoid this problem
we will implement several procedures, as outlined in
(Figure 2). We have previously used the majority of these
strategies to maximize follow-up in multi-centre studies.
Key tactics include: (1) Excluding individuals who are
likely to present problems with follow-up; (2) Prior to
hospital discharge, as well as their own telephone num-
ber, each patient will provide the name and address of
alternate contacts who are likely to be aware of the pa-
tient’s whereabouts; (3) Patients will receive a reminder
card for their next follow-up visit from the clinical re-
search coordinator; and (4) Follow-up visits will coincide
with standard fracture clinic visits. Alternatively, patients
can complete some study visits over the phone for the
visits where no radiographs are required. Additionally,
we will not withdraw patients if the study protocol was
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arm, occurrence of protocol deviations, missed follow-
up visits, etc.).
Minimizing co-intervention and contamination
Any patients who crossover will be analyzed in the
group to which they were allocated, maintaining the
intention to treat approach for the analysis. It remains
possible that surgeons may initially plan upon internal
fixation but decide intra-operatively to replace the hip
with some form of arthroplasty (i.e., hemi-arthroplasty
or total arthroplasty). These patients, who never receive
either internal fixation implant, will be excluded from
the analysis if the decision to choose arthroplasty could
not have plausibly been related to the group to which
the patient was randomized. This decision will be made
by the CAC. In previous trials of internal fixation versus
arthroplasty, 14% of patients randomized to internal fix-
ation implants actually received an arthroplasty [38].
The intraoperative switch to arthroplasty procedures
when internal fixation is planned is related to surgeon
biases for a particular procedure and the inability to ob-
tain a satisfactory reduction of the femoral fracture for
the placement of internal fixation.
Our standardization of management protocols will
limit co-interventions, and we will document the use of
drugs that affect the bone, and major additional proce-
dures that patients undergo. Similarly, the use of medi-
cations that affect bone metabolism will be discouraged,
but not prohibited. Research coordinators will record all
medications such as a bisphosphonates, hormone replace-
ment therapy, selective estrogen receptor modulators, cal-
citonin, and anabolic steroid therapy used concurrently.
Statistical plan
Sample size determination
The determination of sample size is based upon a com-
parison for the primary outcome (revision surgery) of
the sliding hip screw versus multiple cancellous screw
groups. All statistical hypotheses will be assessed using
2-sided significance tests. Alpha levels of 0.05 have been
chosen for the primary and 0.01 for the secondary out-
comes. Previous studies have reported revision surgery
rates in hip fracture patients that have ranged from 0-
44% [39-41], with a weighted pooled risk of 22.7% (95%
CI: 19.6-25.8%). In a pooled estimate of 5 RCTs compar-
ing sliding hip screw fixation with multiple screw fix-
ation in patients with displaced or undisplaced hip
fractures, sliding hip screws reduced the risk of revision
by 32% (95% CI: 3-53%, p = 0.04, Q = 5.3) [22,42-45].
The sample size calculation reflects the proposed pri-
mary analysis, which will use the Cox proportional haz-
ards model, and is based on methods described by
Collett [46]. The goal is to calculate the requirednumber of patients that will yield a sufficient number of
outcome events (revision surgeries) in order to have ad-
equate statistical power for a given size of treatment ef-
fect. This was done by taking into account the
anticipated revision surgery rates in the multiple cancel-
lous screw group, the postulated relative risk reduction
with sliding hip screws, and the rates of mortality and
loss to follow-up. Because some of these inputs are ex-
pected to change over the two year period of follow-up,
the expected number of person-years of follow-up and
the expected numbers of study events in each group
were calculated initially for the first year of follow-up
(year 1). The calculations were then repeated for the sec-
ond year of follow-up (year 2), after having estimated
the number of patients in each group who would sur-
vive, be event-free, and available for continued follow-up
at 12 months post-randomization.
The relative risk reduction was estimated to be 25%
[43]. The decision to use a 25% annual event rate in the
cancellous screws group for year 1 was based upon the
previous literature [25,47] and compelling preliminary
aggregate data (blinded to allocation) from our pilot
study. Informed by the pilot study, annual mortality
rates of 15% and losses to follow-up of 5% were assumed
for each group. The annual event rates by group were
converted into equivalent hazard rates, assuming for
simplicity that the hazard rate would be approximately
constant over year 1. It was calculated that approxi-
mately 58% and 63% of the group receiving cancellous
screws and the group receiving sliding hip screw fixation
would be event-free and available for further follow-up
at the start of year 2. It was assumed that the revision
rate would fall to one-third of its initial value during
year 2 of follow-up (i.e., about 10% in the cancellous
screws group), that the annual mortality rate would be
10%, and that there would again be 5% of patients lost
to follow-up. The sample size was also increased to
allow for an estimated combined 6.8% crossover rate
from the assigned to the alternate treatment, based on
our pilot data.
These assumptions lead to a required total sample size
of 1,441 patients, who will yield an expected number of
353 outcome revisions. For convenience, the target num-
ber of patients was rounded to 1,500. Table 2 shows the
study power for a sample size of 1,500 patients (750 per
group) and a range of possible values for the initial revi-
sion rate and the relative risk reduction, on either side of
the central assumed values. It demonstrates that with
the chosen sample size of 750 per group, there will be a
high likelihood of detecting a RRR of 25% or greater
across the plausible range of revision surgery rates, and
moderate power for slightly lower effect sizes.
After 589 patients completed study follow-up, event
rates were obtained and used to inform power analyses
Table 2 Estimated study power for 750 patients per
treatment arm (N = 1500)
Baseline risk
(Year 1)^ Relative risk reduction
10% 15% 20% 25% 30%
20% 15.9% 30.8% 50.5% 70.5% 86.1%
25% 19.6% 38.7% 61.6% 81.5% 93.5%
30% 23.6% 46.8% 71.7% 89.3% 97.4%
35% 28.2% 55.2% 80.3% 94.5% 99.1%
40% 33.3% 63.6% 87.3% 97.5% 99.7%
*Number of patients per treatment arm, alpha = 0.05.
^Year 2 risk is 1/3 that of year 1.
Bold numbers indicate statistical power range for this study.
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size of 1,000 patients was used in order to obtain a bal-
ance between feasibility of completing recruitment
within a reasonable timeline and obtaining a sample size
that will support plausible hypotheses of treatment effect
and baseline event rates. Based on event rates calculated
from the first 589 patients who completed the study, a
15.5% annual event rate was used for year 1 and a 27.2%
annual event rate was used for year 2. Based on the data
from the completed patients, it was assumed that the
annual mortality rate would be 11.0% (year 1) and 18.2%
(year 2) and that there would be a 12.2% (year 1) and
5.9% (year 2) loss to follow-up. The sample size was
again increased to allow for an estimated combined 6.8%
crossover rate from the assigned to the alternative treat-
ment. Table 3 shows the study power for a sample size
of 1,000 patients (500 per treatment group) and a range
of possible values for the initial revision rate and the
relative risk reduction, on either side of the central as-
sumed values. It demonstrates that with a sample size of
500 per group, there will be a likelihood of detecting a
RRR of 30% or greater across the plausible range of revi-
sion surgery rates, and moderate power for slightly lower
effect sizes.
While the revised assumptions based upon data col-
lected from the first 589 patients to complete follow-up
differ from the initial assumptions, the event annual rate
of revision surgery of 15.5% in year 1 and 27.2% in yearTable 3 Estimated study power for 500 patients per
treatment arm (N = 1,000)
Baseline risk
(Year 1)^ Relative risk reduction
10% 15% 20% 25% 30% 35v 40%
15.5% 14.5% 28.5% 48.1% 69.3% 86.3% 95.7% 99.2%
*Number of patients per treatment arm, alpha = 0.05.
^Year 2 risk is 27.2%.
Bold numbers indicate statistical power range for this study.2 are well within the range of 0-44% that have been pre-
viously reported in the literatures [39-41].
Statistical methods
Primary analysis
All outcome analyses will adhere to the intention to
treat principle. To evaluate the effect of sliding hip screw
versus cancellous screws in time to revision rates, a Cox
proportional hazards model will be used with the follow-
ing covariates that are included in the minimization pro-
cedure: (1) Age (50–80 years or >80 years (81 years or
older)); (2) Undisplaced or displaced femoral neck frac-
tures; (3) Pre-fracture living setting (i.e., institutionalized
or not institutionalized); (4) Pre-fracture functional sta-
tus (i.e., using ambulatory aid or independent ambula-
tor); (5) American Society for Anesthesiologists (ASA)
Class (i.e., Class I/II or III/IV/V); and (6) Clinical site.
The treatment effect will be evaluated using a likeli-
hood ratio test, and the validity of the proportional haz-
ards assumption of the Cox model will be assessed.
Survival rates at each follow-up period will be compared
and then the overall difference between survival curves
with log-rank tests will be evaluated, adjusting for the
covariates. Absolute revision rates, risk reduction, abso-
lute risk reduction, and the number needed to treat with
screws and sideplate will be calculated. All results will
be presented with 95% confidence intervals.
Secondary analysis
We will also examine the relative effect of sliding hip
screw versus cancellous screws on time to mortality,
avascular necrosis, nonunion, implant breakage or fail-
ure, time to fracture healing, and infection (i.e., superfi-
cial and deep) using Cox proportional hazards modeling.
The treatment effect will be evaluated using a likelihood
ratio test, and the validity of the proportional hazards
assumption of the Cox model will be assessed. Survival
rates at each follow-up period will be compared and the
overall difference between survival curves with Log-
Rank tests will be evaluated. Absolute revision rates, risk
reduction, absolute risk reduction, and the number
needed to treat with screws and side plate will be calcu-
lated. All results will be presented with 95% confidence
intervals.
Subgroup analyses
We plan to conduct a single subgroup analysis compar-
ing the effects of multiple screws versus sliding hip
screw in patients with undisplaced and displaced femoral
neck fractures. All analyses will be adjusted for import-
ant determinants of outcome (the prognostic variables
outlined in the randomization section). The analysis plan
is to fit logistic regression models and include treatment
by subgroup interactions to assess whether the magnitude
Table 5 Undisplaced fractures: estimated study power for
250 patients per treatment arm (N = 500)
Baseline risk
(Year 1)^ Relative risk reduction
10% 15% 20% 25% 30% 40%
20% 8.0% 13.2% 20.6% 30.3% 42.0% 68.0%
25% 9.3% 16.0% 25.5% 37.8% 51.3% 79.0%
30% 10.7% 19.1% 31.0% 45.6% 61.4% 87.1%
35% 12.3% 22.6% 36.3% 53.7% 70.3% 92.7%
40% 14.1% 26.5% 43.3% 61.8% 78.2% 96.3%
*Number of patients per treatment arm, alpha = 0.05.
^Year 2 risk is 1/3 that of year 1.
Bold numbers indicate statistical power range for this study.
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subgroups. The survey and population-based data from
Sweden suggests that two-thirds of all included fractures
will be displaced [48]. Thus, approximately 1,000 dis-
placed fractures (500 per group) and 500 undisplaced frac-
tures (250 per group) can be expected. The weighted risk
of revision in displaced fractures is 30.2%, (95% CI = 24.1,
6.4) and 20.4% (95% CI =17.4, 23.4%) in undisplaced frac-
tures. The power tables suggest that the study will be able
to detect relative risk reductions of 30% or greater with
sliding hip screw compared to multiple cancellous screws
in displaced fractures (Table 4).
Previous randomized trials in patients with displaced
fractures suggest that relative risk reductions with sliding
hip screw as high as 48% are plausible [22,43-45]. Simi-
larly, in undisplaced fractures the study will have at least
80% power to detect relative risk reductions of 40% or
greater with sliding hip screws (Table 5).
Previous trials suggest risk reductions greater than
50% in undisplaced fractures [42,49]. If these previous
estimates are correct, the current study will have adequate
power for these analyses.
Interim analysis
An interim analysis will not be conducted. The trial will not
be stopped early for benefit. The Data Safety Monitoring
Board (DSMB) will monitor Adverse Events (AEs) and
may make recommendations to the Principal Investigators
and Steering Committee to stop the study for harm only.
Data management
The Case Report Forms (CRFs) will be the primary data
collection tool for the study. All data requested on the
CRF must be recorded. An Electronic Data Capture sys-
tem will be used to submit data to the Methods Centre
located at McMaster University. Upon receipt of the
data, the personnel at the Methods Centre will make a
visual check of the data and they will query all missing
data, implausible data, and inconsistencies.Table 4 Displaced fractures: estimated study power for
500 patients per treatment arm (N = 1,000)
Baseline risk
(Year 1)^ Relative risk reduction
10% 15% 20% 25% 30% 40%x
20% 12.0% 22.1% 36.3% 53.2% 70.1% 93.0%
25% 14.5% 27.6% 45.3% 64.5% 81.0% 97.5%
30% 17.2% 33.5% 45.3% 74.4% 88.9% 99.2%
35% 20.3% 40.0% 63.2% 82.7% 94.1% 99.8%
40% 23.8% 47.0% 71.7% 89.2% 97.2% 100.0%
*Number of patients per treatment arm, alpha = 0.05.
^Year 2 risk is 1/3 that of year 1.
Bold numbers indicate statistical power range for this study.Ethical considerations
All patients will be provided a consent form describing
the study and providing sufficient information to make
an informed decision about their participation in this
study. The consent form will be submitted with the
protocol for review and approval by the REB/Institu-
tional Review Board (IRB) for the study. The formal con-
sent of a patient, using the REB/IRB-approved consent
form, must be obtained before that patient undergoes
any study procedure. Any amendments to the study
protocol which may affect the conduct of the study, or
the potential safety of or benefits to patients will require
a formal amendment to the protocol requiring approval
by McMaster University’s REB and local research ethics
boards for clinical sites.
Information about study patients will be kept confi-
dential and will be managed in accordance with the fol-
lowing rules: (1) All study-related information will be
stored securely at the clinical site; (2) All study patient
information will be stored in locked file cabinets and ac-
cessible only to study personnel; (3) All CRFs will be
identified only by a coded patient number and initials;
(4) All records that contain patient names, or other
identifying information, will be stored separately from
the study records that are identified only by the coded
patient number and initials; and (5) All local databases
will be password protected.
Study committees
Steering committee
The Steering Committee is comprised of orthopaedic sur-
geons, a statistician, and research methodologists. The
Steering Committee will provide guidance and direction
to the overall trial.
Data safety and monitoring board
The DSMB is comprised of Medical Doctors, a Safety
Officer, and a Statistician who remain completely inde-
pendent of the study investigators. The DSMB will review
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cipal Investigators and the Steering Committee on items
related to patient safety.
Dissemination
Results from the primary manuscript will be submitted
for publication regardless of whether or not there are
significant findings. Every attempt will be made to ensure
that the amount of time between completion of data col-
lection and release of study findings are minimized.
Only the Methods Centre will have access to the full
trial dataset. Data for the primary publication will be an-
alyzed exclusively by the Methods Centre. Requests for
access to the full trial dataset for secondary publications
are encouraged and can be initiated through a written
request to Methods Centre personnel.
Discussion
Most of the current literature evaluating the efficacy of
internal fixation at treating hip fractures is focused on
the comparison between internal fixation and arthro-
plasty, which does not allow for a direct comparison of
different methods of internal fixation. The RCTs that
directly evaluate different types of internal fixation have
been too small to definitively guide Orthopaedic prac-
tices as they lack sufficient power to reliably detect im-
portant treatment effects and some contain important
methodological limitations [16,25]. FAITH will be the
largest trial to date informing the question of the impact
of cancellous screws and sliding hip screws on outcomes
in patients with femoral neck fractures. With over 1000
patients, FAITH will have adequate power to detect im-
portant treatment effects and will help to inform Ortho-
paedic practice. FAITH will include patients from North
America, Europe, Asia, and Australia making results
generalizable to several different geographic populations.
Our previous trial evaluating reamed versus non-
reamed nailing in over 1,300 patients with tibial shaft
fractures (SPRINT) set a new benchmark for the con-
duct of RCTs in Orthopaedic surgery [50,51]. The
FAITH trial expands upon the successful methodology
employed in SPRINT and will set the bar higher as we
expand our collaboration worldwide and recruit a larger
number of patients, while maintaining methodological
rigor. Ultimately, this RCT will move Orthopaedic surgical
trials one step closer to the standards of global impact
RCTs that are currently conducted in cardiovascular medi-
cine and cerebrovascular surgery (e.g. POISE Trial Investi-
gators, 2006; PROTECT Investigators, 2011) [52,53].
Since treatment allocation is concealed there will be
no risk of conscious or unconscious selection bias on
the part of the researchers, as can occur when it is pos-
sible for researchers to predict treatment assignment.
Further, minimization will be used to ensure prognosticbalance between intervention groups for relevant patient
factors. The minimization approach evaluates the mar-
ginal distribution of each prognostic variable and then
sums over the variables as each patient is assigned to a
treatment group. Unlike random permuted block within
strata, minimization works toward minimizing the total
imbalance for all factors together instead of considering
mutually exclusive subgroups [26] which may be consid-
ered an additional strength.
One limitation of the FAITH trial is the inability to
blind patients, surgeons, and outcome adjudicators. Pa-
tients cannot be blinded as the two devices leave unique
scarring patterns and surgeons cannot be blinded as the
devices are easily discernible. It was planned that out-
come adjudicators would be blinded to study treatment
arm by digitally superimposing cancellous screws and
the sliding hip screw on the same x-ray image for the as-
sessments of quality of fracture reduction, fracture heal-
ing, infection, and avascular necrosis. However, after
piloting this approach we found that it was still possible
to often correctly identify the true treatment, and that
difficulties with adjudication were created because of too
much bone being covered. Therefore this approach was
found to be infeasible for adjudicating and as a result
outcome adjudicators will not be blinded to study treat-
ment during their assessment of patients’ radiographic
characteristics and quality of surgery. However, as revi-
sion surgery (the primary outcome) is objective, it is ex-
pected that a lack of blinding will not introduce
significant threats to validity. To limit the minimal risk
of bias that unblinded adjudication can create, a CAC
will be used and consensus will be required on all adju-
dication events.
There is inconclusive evidence within the literature re-
garding operative method of internal fixation for femoral
neck fractures. Prior evidence has suggested sliding hips
screws may be superior to cancellous screws, but these
findings have been based on studies with small sample
sizes and low events numbers [25]. Advocates of mul-
tiple cancellous screws focus upon its superior torsional
stability, limited disruption of femoral head blood sup-
ply, and minimally invasive insertion, while proponents
of the sliding hip screw believe its superior biomechan-
ical properties and greater fracture stability in osteopor-
otic bone should decrease the need for revision surgery.
Despite the evidence suggesting the superiority of sliding
hip screws, 90% of surgeons preferred cancellous screws
over sliding hip screws for treating undisplaced fractures
and 68% preferred cancellous screws over sliding hip
screws in treating displaced fractures. Definitively identi-
fying the optimal surgical approach to the initial man-
agement of femoral neck fractures has enormous
potential to improve the lives of hundreds of thousands
of individuals who suffer these injuries each year. The
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posed interventions will have wide applicability where
trauma burden and disability from hip fractures is high.
This trial will not only change current orthopaedic practice,
but will set a benchmark for the conduct of future
orthopaedic trials.
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